Telavant

Telavant is owned by Sumitomo Chemical.

Sumitomo Chemical is one of the...

• Forbes Global 2000 (#1009);
• Nikkei 225;
• Topix.

Sumitomo Chemical is a company listed under the stock ticker 4005 (JP).

Sumitomo Chemical has a direct presence in 6 countries.

Sumitomo Chemical has 27 subsidiaries including Asahi Chemical, Covant Therapeutics and Datavant.

They are in:

• Biotechnology57%
• Chemicals25%
• Other18%

View the org chart displaying its 5 main executives

Most searched biographies at Telavant

• Frank Torti, Chairman and Chief Executive Officer
• Bittoo Kanwar, Chief Medical Officer
• Amy Mahery, Chief Commercial Officer

Create your alert
to follow the executive moves at Telavant.

Sumitomo Chemical has 2,292 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Deepull (Spain).

Popular M&A news in Biotechnology

• Rapport Therapeutics has just announced a $154 Million fundraising (posted on June 11 2024).
• Amber Therapeutics has just announced a $100 Million fundraising (posted on June 10 2024).
• Restor3d has just announced a $70 Million fundraising (posted on June 8 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Carl Gordon - Director at Adicet Bio
• Kristina Burow - Director at Scholar Rock

Learn more about the Biotechnology industry >

Press releases by Telavant

• Roche Enters Into a Definitive Agreement to Acquire Telavant Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease From Roivant | Roivant Sciences Ltd.
• Roivant Announces Statistically Significant and Clinically Meaningful Results from the Induction Period of TUSCANY-2, a Large Global Phase 2b Study of Subcutaneous RVT-3101 for the Treatment of Ulcerative Colitis in Both the Overall and the Biomarker Posi
• Roivant and Pfizer Form New Vant Company Focused on Developing TL1A Drug Candidate for Inflammatory and Fibrotic Diseases | Roivant Sciences Ltd.
• Roivant Reports Chronic Period Data for RVT-3101 from the TUSCANY-2 Phase 2b Study in Ulcerative Colitis, Demonstrating Improved Efficacy from the Induction to Chronic Period | Roivant Sciences Ltd.
• Telavant, a Roivant Company, Advances Inflammatory Bowel Disease Program with First Patient Dosed in Global Phase 2 Trial of Novel Anti-TL1A Antibody RVT-3101 in Crohn’s Disease | Roivant Sciences Ltd.
• News & Presentations | Telavant
• View more press releases Close

Social media about Telavant

• Telavant on Wikipedia, Google News & Yahoo Finance
• Telavant on LinkedIn, Twitter & YouTube

Contact by email its executives including Tiago Girão

Call Telavant at +1 212...

View the org chart

Register to receive your alert

Report an error